FDA Approves Drug That Doubles Pancreatic Cancer Survival

For the first time in decades, patients with advanced pancreatic cancer have a treatment that could give them significantly more time with their families.

The FDA approved daraxonrasib (brand name Rasonque) on Wednesday, a daily pill that targets RAS proteins driving tumor growth in pancreatic cancer. The approval marks a turning point for a disease that has stubbornly resisted treatment for generations.

The numbers tell a powerful story. In a clinical trial with 500 patients, those taking daraxonrasib lived a median of 13 months compared to 6.7 months with standard chemotherapy. That's nearly double the survival time.

"This is an exceptional moment for patients with pancreatic cancer," said Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. The drug gives patients "a new treatment option and new hope."

One patient named Jim shared his experience on Good Morning America in June. After starting daraxonrasib, a tumor in his liver that had spread from his pancreas shrank by 50%. "It was incredible news," he said.

Pancreatic adenocarcinoma represents only 3.2% of cancer diagnoses but accounts for a disproportionately high share of cancer deaths. The disease is usually detected late, progresses aggressively, and until now has had limited treatment options.

The drug works by targeting multiple forms of RAS proteins, which are present in about 95% of pancreatic cancer cases. This targeted approach represents years of research finally paying off for patients who desperately needed better options.

Why This Inspires

This approval shows what happens when researchers refuse to give up on difficult challenges. Pancreatic cancer has long been considered one of the hardest cancers to treat, but scientists kept searching for solutions.

The FDA fast-tracked the review, cutting the timeline from 12 to 10 months through a priority program. Dr. Angelo de Claro from the FDA's Oncology Center of Excellence called the results "unprecedented in an area of high unmet need."

Even more exciting: researchers believe this type of targeted treatment could help patients with other hard-to-treat cancers. The approach opens doors that were previously closed.

The drug is approved for adults with metastatic pancreatic adenocarcinoma who have tried at least one other treatment. That means thousands of patients now have access to a therapy that could meaningfully extend their lives.

Medical breakthroughs don't happen overnight, but when they arrive, they change everything for the people who need them most.